We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > LSALT peptide

News List

University of Calgary Joins Trial of LSALT Peptide for Complications in Hospitalized COVID-19 Patients americanpharmaceuticalreview
January 12, 2021
Arch Biopartners announced the University of Calgary Cumming School of Medicine has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications ...
First Patient Dosed in Trial to Treat Complications in COVID-19 americanpharmaceuticalreview
October 22, 2020
Arch Biopartners has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to ...